IMMUNOe Research Center

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

Richard Dodel, Axel Rominger, Peter Bartenstein et al. · The Lancet Neurology · 2013 · 183 citations · Full text

Geriatric Neurology, Alzheimer's Disease, Medicine +12

Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency

John B. Hagan, Mary Beth Fasano, Sheldon Spector et al. · Journal of Clinical Immunology · 2010 · 130 citations · Full text

Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033

Jonathan Q. Tran, Jitesh Rana, Frederik Barkhof et al. · Neurology Neuroimmunology & Neuroinflammation · 2014 · 121 citations · Full text

Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary Immunodeficiency

Richard L. Wasserman, Isaac Melamed, Robert P. Nelson et al. · Clinical Pharmacokinetics · 2011 · 64 citations

Primary Immunodeficiency, Treatment And Prevention, Medicine +4

Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America

Daniel Suez, Mark R. Stein, Sudhir Gupta et al. · Journal of Clinical Immunology · 2016 · 62 citations · Full text